Drug intelligence / Profile preview

JMB-2201

Development stage: Preclinical
Lead developer: Guangzhou Jiayue Pharmaceutical Technology

Overview

JMB-2201 is an early-stage biologic candidate under development by Guangzhou Jiayue Pharmaceutical Technology (also known as Jeyou Pharma). As of 2024, the program is in the discovery or preclinical phase, represented by a 20% progress marker in the company's pipeline. JMB-2201 is specifically being developed for the treatment of metabolic diseases and obesity. While the exact biological target and mechanism of action remain undisclosed, the asset is part of Jeyou Pharma's strategic expansion into the metabolic therapeutic space, complementing its existing portfolio in nephrology and oncology. The 'JMB' designation indicates it is part of the company's macromolecule biologic pipeline, distinguishing it from its 'JMKX' small molecule series.

Other names: JMB-2201JMB2201JMB 2201

Beyond the preview

Go deeper on JMB-2201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMB-2201.

Explore the full profile